A BILL 
To amend the Public Health Service Act to establish insulin 
assistance programs, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Emergency Access to 
4
Insulin Act of 2019’’. 
5
SEC. 2. INSULIN ASSISTANCE PROGRAMS. 
6
(a) IN GENERAL.—Part B of title III of the Public 
7
Health Service Act (42 U.S.C. 243 et seq.) is amended 
8
by adding at the end the following: 
9
01:10 Aug 14, 2019
H4010
2 
•HR 4010 IH
‘‘SEC. 320B. INSULIN ASSISTANCE PROGRAMS. 
1
‘‘(a) ESTABLISHMENT OF PROGRAM OF GRANTS TO 
2
STATES, INDIAN
TRIBES, 
AND
TRIBAL
ORGANIZA-
3
TIONS.— 
4
‘‘(1) IN
GENERAL.—The Secretary, acting 
5
through the Director of the Centers for Disease 
6
Control and Prevention, shall, not later than 1 year 
7
after the date of enactment of this section, make 
8
grants to States, Indian tribes, and tribal organiza-
9
tions for the purpose of carrying out programs to as-
10
sist eligible individuals in obtaining insulin in ac-
11
cordance with paragraph (4). 
12
‘‘(2) GRANT AND CONTRACT AUTHORITY FOR 
13
STATES, INDIAN
TRIBES, AND
TRIBAL
ORGANIZA-
14
TIONS.— 
15
‘‘(A) IN GENERAL.—A State, Indian tribe, 
16
or tribal organization receiving a grant under 
17
paragraph (1) may, subject to subparagraph 
18
(B), expend the grant to carry out the purpose 
19
described in such paragraph through grants or 
20
contracts to public or private entities, including 
21
local governments. 
22
‘‘(B) CERTAIN APPLICATIONS.—If a non-
23
profit private entity and a private entity that is 
24
not a nonprofit entity both submit applications 
25
to a State, Indian tribe, or tribal organization 
26
01:10 Aug 14, 2019
H4010
3 
•HR 4010 IH
to receive an award of a grant or contract 
1
under subparagraph (A), the State, Indian 
2
tribe, or tribal organization may give priority to 
3
the application submitted by the nonprofit pri-
4
vate entity in any case in which the State, In-
5
dian tribe, or tribal organization determines 
6
that the quality of such application is equiva-
7
lent to the quality of the application submitted 
8
by the other private entity. 
9
‘‘(3) ALLOTMENT.—Each State, Indian tribe, 
10
or tribal organization that applies for a grant in ac-
11
cordance with subsection (e) shall receive a grant 
12
under this section in an amount that is equal to the 
13
sum of— 
14
‘‘(A) a minimum amount determined by 
15
the Secretary; and 
16
‘‘(B) an additional amount based on cri-
17
teria established by the Secretary, which may 
18
include the ability of the State, Indian tribe, or 
19
tribal organization to successfully assist individ-
20
uals in seeking eligibility for Federal or State- 
21
funded programs as described in paragraph 
22
(4)(A)(iv). 
23
‘‘(4) PROGRAM COMPONENTS.— 
24
01:10 Aug 14, 2019
H4010
4 
•HR 4010 IH
‘‘(A) IN GENERAL.—A State, Indian tribe, 
1
or tribal organization carrying out a program 
2
supported by a grant under this subsection 
3
shall use the grant funds to— 
4
‘‘(i) purchase insulin; 
5
‘‘(ii) issue insulin cards to eligible in-
6
dividuals in accordance with subparagraph 
7
(B); 
8
‘‘(iii) enter into agreements with phar-
9
macies— 
10
‘‘(I) for such pharmacies to fill 
11
prescriptions for individuals displaying 
12
valid insulin cards that are issued in 
13
accordance with subparagraph (B) at 
14
no cost to such individuals; and 
15
‘‘(II) for the State, Indian tribe, 
16
or tribal organization to pay such 
17
pharmacies for insulin filled for a pre-
18
scription described in subclause (I); 
19
and 
20
‘‘(iv) assist individuals in seeking eli-
21
gibility for Federal or State-funded pro-
22
grams which may provide coverage for in-
23
sulin or otherwise assist such individuals in 
24
obtaining insulin. 
25
01:10 Aug 14, 2019
H4010
5 
•HR 4010 IH
‘‘(B) INSULIN CARDS.— 
1
‘‘(i) APPLICATION.—An eligible indi-
2
vidual seeking an insulin card through a 
3
program supported by a grant under this 
4
subsection shall submit an application to 
5
the State, Indian tribe, or tribal organiza-
6
tion receiving the grant, at such time, in 
7
such manner, and containing such infor-
8
mation as the State, Indian tribe, or tribal 
9
organization may reasonably require for 
10
purposes of this subsection, including— 
11
‘‘(I) 
documentation 
indicating 
12
proof of— 
13
‘‘(aa) in the case of a grant 
14
awarded to a State, residency in 
15
the State; 
16
‘‘(bb) in the case of a grant 
17
awarded to an Indian tribe, mem-
18
bership in the Indian tribe; or 
19
‘‘(cc) in the case of a grant 
20
awarded to a tribal organization, 
21
membership in the Indian tribe 
22
or Indian community served by 
23
the tribal organization; 
24
01:10 Aug 14, 2019
H4010
6 
•HR 4010 IH
‘‘(II) a prescription for insulin 
1
that is prescribed to the individual; 
2
‘‘(III) a statement that, to the 
3
best of the individual’s knowledge, the 
4
individual is an uninsured individual 
5
or an underinsured individual; and 
6
‘‘(IV) if the individual is an 
7
underinsured individual, the name of 
8
the high-deductible health plan in 
9
which the individual is enrolled and 
10
any unique identifier of the plan, such 
11
as a policy number. 
12
‘‘(ii) INITIAL CARD.— 
13
‘‘(I) IN GENERAL.—A State, In-
14
dian tribe, or tribal organization car-
15
rying out a program supported by a 
16
grant under this subsection shall issue 
17
an initial insulin card to each indi-
18
vidual that submits an application to 
19
the State, Indian tribe, or tribal orga-
20
nization meeting the requirements 
21
under clause (i). 
22
‘‘(II) TIMING.—A State, Indian 
23
tribe, or tribal organization that re-
24
ceives an application under clause (i) 
25
01:10 Aug 14, 2019
H4010
7 
•HR 4010 IH
from an individual shall issue an ini-
1
tial insulin card to such individual not 
2
later than 5 business days after re-
3
ceiving such application. 
4
‘‘(III) SUPPLY.—An initial insu-
5
lin card issued to an individual under 
6
this clause shall be valid for an ap-
7
proximate 7-day supply of insulin that 
8
is appropriate for the individual based 
9
on the prescription for the individual 
10
provided in the application under 
11
clause (i) and packaging and proc-
12
essing practices for insulin. 
13
‘‘(iii) 3-MONTH
CARDS.—Not later 
14
than 12 business days after an individual 
15
submits an application under clause (i) to 
16
a State, Indian tribe, or tribal organiza-
17
tion, the State, Indian tribe, or tribal orga-
18
nization shall— 
19
‘‘(I) determine whether the indi-
20
vidual is an eligible individual; and 
21
‘‘(II) if the individual is an eligi-
22
ble individual, issue the individual an 
23
insulin card that is valid for an ap-
24
proximate 90-day supply of insulin 
25
01:10 Aug 14, 2019
H4010
8 
•HR 4010 IH
that is appropriate for the individual 
1
based on the prescription provided in 
2
the application under clause (i) and 
3
packaging and processing practices 
4
for insulin. 
5
‘‘(iv) RENEWAL OF CARDS.— 
6
‘‘(I) 3-MONTH CARDS.—An eligi-
7
ble individual that is issued an insulin 
8
card under clause (iii) may apply to 
9
renew such card in accordance with a 
10
process established by the State, In-
11
dian tribe, or tribal organization. 
12
‘‘(II) 
LIMITATION.—An 
indi-
13
vidual that submits an application 
14
under clause (i) and is denied an insu-
15
lin card under clause (ii) or (iii) may 
16
not submit another application under 
17
clause (i) for the 1-year period begin-
18
ning on the date on which the indi-
19
vidual is denied such card. 
20
‘‘(b) REQUIREMENT OF MATCHING FUNDS.— 
21
‘‘(1) IN
GENERAL.—The Secretary may not 
22
make a grant under subsection (a) unless the State, 
23
Indian tribe, or tribal organization involved agrees, 
24
with respect to the costs to be incurred by the State, 
25
01:10 Aug 14, 2019
H4010
9 
•HR 4010 IH
Indian tribe, or tribal organization in carrying out 
1
the purpose described in subsection (a)(1), to make 
2
available non-Federal contributions (in cash or in- 
3
kind under paragraph (2)) toward such costs in an 
4
amount equal to not less than $1 for each $3 of 
5
Federal funds provided in the grant. Such contribu-
6
tions may be made directly or through donations 
7
from public or private entities. 
8
‘‘(2) DETERMINATION
OF
AMOUNT
OF
NON- 
9
FEDERAL CONTRIBUTION.— 
10
‘‘(A) IN GENERAL.—Non-Federal contribu-
11
tions required in paragraph (1) may be in cash 
12
or in-kind, fairly evaluated, including equipment 
13
or services (and excluding indirect or overhead 
14
costs). Amounts provided by the Federal Gov-
15
ernment, or services assisted or subsidized to 
16
any significant extent by the Federal Govern-
17
ment, may not be included in determining the 
18
amount of such non-Federal contributions. 
19
‘‘(B) 
MAINTENANCE
OF
EFFORT.—In 
20
making a determination of the amount of non- 
21
Federal contributions for purposes of paragraph 
22
(1), the Secretary may include only non-Federal 
23
contributions in excess of the average amount 
24
of non-Federal contributions made by the State, 
25
01:10 Aug 14, 2019
H4010
10 
•HR 4010 IH
Indian tribe, or tribal organization involved to-
1
ward the purpose described in subsection (a)(1) 
2
for the 2-year period preceding the first fiscal 
3
year for which the State, Indian tribe, or tribal 
4
organization is applying to receive a grant 
5
under subsection (a). 
6
‘‘(C) INCLUSION OF RELEVANT NON-FED-
7
ERAL
CONTRIBUTIONS
FOR
MEDICAID.—In 
8
making a determination of the amount of non- 
9
Federal contributions for purposes of paragraph 
10
(1), the Secretary shall, subject to subpara-
11
graphs (A) and (B) of this paragraph, include 
12
any non-Federal amounts expended pursuant to 
13
title XIX of the Social Security Act by the 
14
State, Indian tribe, or tribal organization re-
15
lated to insulin dispensed to individuals eligible 
16
for medical assistance under such title. 
17
‘‘(c) ADDITIONAL REQUIRED AGREEMENTS.— 
18
‘‘(1) STATEWIDE PROVISION OF SERVICES.— 
19
‘‘(A) IN
GENERAL.—The Secretary may 
20
not make a grant under subsection (a) unless 
21
the State, Indian tribe, or tribal organization 
22
involved agrees that services and activities 
23
under the grant will be made available through-
24
out the State (including availability to members 
25
01:10 Aug 14, 2019
H4010
11 
•HR 4010 IH
of any Indian tribe or tribal organization in the 
1
State), Indian tribe, or tribal organization. 
2
‘‘(B) WAIVER.— 
3
‘‘(i) IN
GENERAL.—The Secretary 
4
may waive the requirement established in 
5
subparagraph (A) for a State, Indian tribe, 
6
or tribal organization if the Secretary de-
7
termines that compliance by the State, In-
8
dian tribe, or tribal organization with the 
9
requirement would result in an inefficient 
10
allocation of resources with respect to car-
11
rying out the purpose described in sub-
12
section (a)(1). 
13
‘‘(ii) INDIAN TRIBES AND TRIBAL OR-
14
GANIZATIONS.—If an Indian tribe or tribal 
15
organization is receiving a grant under 
16
subsection (a) and the State in which the 
17
tribe or organization is located is receiving 
18
a grant under subsection (a), the require-
19
ment under subparagraph (A) for the 
20
State regarding availability to the tribe or 
21
organization is deemed to have been 
22
waived under this subparagraph. 
23
‘‘(2) RELATIONSHIP TO ITEMS AND SERVICES 
24
UNDER OTHER PROGRAMS.— 
25
01:10 Aug 14, 2019
H4010
12 
•HR 4010 IH
‘‘(A) IN
GENERAL.—The Secretary may 
1
not make a grant under subsection (a) unless 
2
the State, Indian tribe, or tribal organization 
3
involved agrees that the grant will not be ex-
4
pended to make payment for any item or serv-
5
ice to the extent that payment has been made, 
6
or can reasonably be expected to be made, with 
7
respect to such item or service— 
8
‘‘(i) except as provided in subpara-
9
graph (B), under any State compensation 
10
program, under an insurance policy, or 
11
under any Federal or State health benefits 
12
program; or 
13
‘‘(ii) by an entity that provides health 
14
services on a prepaid basis. 
15
‘‘(B) EXCEPTION.—The requirement under 
16
subparagraph (A)(i) shall not apply with re-
17
spect to coverage under a high-deductible health 
18
plan. 
19
‘‘(3) LIMITATION
ON
ADMINISTRATIVE
EX-
20
PENSES.—The Secretary may not make a grant 
21
under subsection (a) unless the State, Indian tribe, 
22
or tribal organization involved agrees that not more 
23
than 10 percent of the grant will be expended for 
24
administrative expenses with respect to the grant. 
25
01:10 Aug 14, 2019
H4010
13 
•HR 4010 IH
‘‘(4) RECORDS
AND
AUDITS.—The Secretary 
1
may not make a grant under subsection (a) unless 
2
the State, Indian tribe, or tribal organization in-
3
volved agrees that— 
4
‘‘(A) the State, Indian tribe, or tribal orga-
5
nization will establish such fiscal control and 
6
fund accounting procedures as may be nec-
7
essary to ensure the proper disbursal of, and 
8
accounting for, amounts received by the State, 
9
Indian tribe, or tribal organization under such 
10
subsection; 
11
‘‘(B) upon request, the State, Indian tribe, 
12
or tribal organization will provide records main-
13
tained pursuant to subparagraph (A) to the 
14
Secretary or the Comptroller General of the 
15
United States for purposes of auditing the ex-
16
penditures by the State, Indian tribe, or tribal 
17
organization of the grant; and 
18
‘‘(C) the State, Indian tribe, or tribal orga-
19
nization will keep such records as the Secretary 
20
shall prescribe, including— 
21
‘‘(i) records that fully disclose— 
22
‘‘(I) the amount and disposition 
23
by the State, Indian tribe, or tribal 
24
01:10 Aug 14, 2019
H4010
14 
•HR 4010 IH
organization of the proceeds of such 
1
grant; 
2
‘‘(II) the total cost of the project 
3
or undertaking intended to be carried 
4
out through the grant; and 
5
‘‘(III) the amount of that portion 
6
of the cost of the project or under-
7
taking supplied by sources other than 
8
the grant; and 
9
‘‘(ii) such other records as the Sec-
10
retary determines appropriate for facili-
11
tating an effective audit of grants awarded 
12
under this section. 
13
‘‘(5) REPORTS.— 
14
‘‘(A) REPORTS TO THE SECRETARY.—The 
15
Secretary may not make a grant under sub-
16
section (a) unless the State, Indian tribe, or 
17
tribal organization involved agrees to submit to 
18
the Secretary such reports as the Secretary 
19
may require with respect to the grant, including 
20
a report on— 
21
‘‘(i) the types of problems and inquir-
22
ies encountered by individuals applying for 
23
or receiving insulin through a program 
24
supported by such grant; 
25
01:10 Aug 14, 2019
H4010
15 
•HR 4010 IH
‘‘(ii) the number of insulin products 
1
dispensed and the unit costs for those 
2
products during the period covered by the 
3
report; 
4
‘‘(iii) the number of pharmacies par-
5
ticipating in the program during the period 
6
covered by the report; 
7
‘‘(iv) summary data on the individuals 
8
applying for or receiving insulin through 
9
the program; and 
10
‘‘(v) any other information the Sec-
11
retary shall determine necessary to provide 
12
oversight of the grants made under this 
13
section. 
14
‘‘(B) 
HIGH-DEDUCTIBLE
HEALTH 
15
PLANS.—The Secretary may not make a grant 
16
under subsection (a) unless the State, Indian 
17
tribe, or tribal organization involved agrees to, 
18
as soon as practicable after each time the State, 
19
Indian tribe, or tribal organization provides 
20
payment to a pharmacy for insulin for an 
21
underinsured individual, submit to the high-de-
22
ductible health plan in which the individual is 
23
enrolled information on the amount of such 
24
01:10 Aug 14, 2019
H4010
16 
•HR 4010 IH
payment in order for such plan to comply with 
1
the requirements under section 2710. 
2
‘‘(d) 
DESCRIPTION
OF
INTENDED
USES
OF 
3
GRANT.—The Secretary may not make a grant under sub-
4
section (a) unless— 
5
‘‘(1) the State, Indian tribe, or tribal organiza-
6
tion involved submits to the Secretary a description 
7
of the purposes for which the State, Indian tribe, or 
8
tribal organization intends to expend the grant; 
9
‘‘(2) the description identifies the populations, 
10
areas, and localities in the State, or under the juris-
11
diction of the Indian tribe or tribal organization, 
12
with a need for a program to assist individuals in 
13
obtaining insulin in accordance with subsection (a); 
14
‘‘(3) the description provides information relat-
15
ing to the services and activities to be provided, in-
16
cluding a description of the manner in which the 
17
services and activities will be coordinated with any 
18
similar services or activities of public or private enti-
19
ties; and 
20
‘‘(4) the description provides assurances that 
21
the grant funds will be used in the most cost-effec-
22
tive manner. 
23
‘‘(e) REQUIREMENT OF SUBMISSION OF APPLICA-
24
TION.—The Secretary may not make a grant under sub-
25
01:10 Aug 14, 2019
H4010
17 
•HR 4010 IH
section (a) unless an application for the grant is submitted 
1
to the Secretary, the application contains the description 
2
of intended uses required under subsection (d), and the 
3
application is in such form, is made in such manner, and 
4
contains such agreements, assurances, and information as 
5
the Secretary determines to be necessary to carry out this 
6
section. 
7
‘‘(f) TECHNICAL ASSISTANCE
AND PROVISION
OF 
8
SUPPLIES AND SERVICES IN LIEU OF GRANT FUNDS.— 
9
‘‘(1) TECHNICAL ASSISTANCE.—The Secretary 
10
may provide training and technical assistance with 
11
respect to the planning, development, and operation 
12
of any program or service carried out pursuant to 
13
subsection (a). The Secretary may provide such 
14
technical assistance directly or through grants to, or 
15
contracts with, public or private entities. 
16
‘‘(2) PROVISION OF SUPPLIES AND SERVICES IN 
17
LIEU OF GRANT FUNDS.— 
18
‘‘(A) IN GENERAL.—Upon the request of a 
19
State, Indian tribe, or tribal organization re-
20
ceiving a grant under subsection (a), the Sec-
21
retary may, subject to subparagraph (B), pro-
22
vide supplies, equipment, and services for the 
23
purpose of aiding the State, Indian tribe, or 
24
tribal organization in carrying out such sub-
25
01:10 Aug 14, 2019
H4010
18 
•HR 4010 IH
section and, for such purpose, may detail to the 
1
State, Indian tribe, or tribal organization any 
2
officer or employee of the Department of 
3
Health and Human Services. 
4
‘‘(B) CORRESPONDING REDUCTION IN PAY-
5
MENTS.—With respect to a request described in 
6
subparagraph (A), the Secretary shall reduce 
7
the amount of payments under the grant under 
8
subsection (a) to the State, Indian tribe, or 
9
tribal organization involved by an amount equal 
10
to the costs of detailing personnel (including 
11
pay, allowances, and travel expenses) and the 
12
fair market value of any supplies, equipment, or 
13
services provided by the Secretary. The Sec-
14
retary shall, for the payment of expenses in-
15
curred in complying with such request, expend 
16
the amounts withheld. 
17
‘‘(g) EVALUATIONS AND REPORTS.— 
18
‘‘(1) EVALUATIONS.—The Secretary shall, di-
19
rectly or through contracts with public or private en-
20
tities, provide for annual evaluations of programs 
21
carried out pursuant to subsection (a). Such evalua-
22
tions shall include evaluations of— 
23
‘‘(A) the extent to which States, Indian 
24
tribes, and tribal organizations carrying out 
25
01:10 Aug 14, 2019
H4010
19 
•HR 4010 IH
such programs are in compliance with sub-
1
section (a) and with subsection (c)(1); and 
2
‘‘(B) the extent to which each State, In-
3
dian tribe, or tribal organization receiving a 
4
grant under this section is in compliance with 
5
subsection (b), including identification of— 
6
‘‘(i) the amount of the non-Federal 
7
contributions by the State, Indian tribe, or 
8
tribal organization for the preceding fiscal 
9
year, disaggregated according to the source 
10
of the contributions; and 
11
‘‘(ii) the proportion of such amount of 
12
non-Federal contributions relative to the 
13
amount of Federal funds provided through 
14
the grant to the State, Indian tribe, or 
15
tribal organization for the preceding fiscal 
16
year. 
17
‘‘(2) REPORTS TO CONGRESS.—The Secretary 
18
shall, not later than 1 year after the date of the en-
19
actment of the Emergency Access to Insulin Act of 
20
2019, and annually thereafter, submit to the Com-
21
mittee on Health, Education, Labor, and Pensions 
22
of the Senate and the Committee on Energy and 
23
Commerce of the House of Representatives a report 
24
summarizing evaluations carried out under para-
25
01:10 Aug 14, 2019
H4010
20 
•HR 4010 IH
graph (1) during the preceding fiscal year and mak-
1
ing such recommendations for administrative and 
2
legislative initiatives with respect to this section as 
3
the Secretary determines to be appropriate, includ-
4
ing recommendations regarding compliance by the 
5
States, Indian tribes, and tribal organizations with 
6
subsection (a) and with subsection (c)(1). 
7
‘‘(h) FUNDING FOR GENERAL PROGRAM.— 
8
‘‘(1) AUTHORIZATION
OF
APPROPRIATIONS.— 
9
For the purpose of carrying out this section, there 
10
are authorized to be appropriated such sums as may 
11
be necessary. 
12
‘‘(2) SET-ASIDE
FOR
TECHNICAL
ASSISTANCE 
13
AND PROVISION OF SUPPLIES AND SERVICES.—Of 
14
the amounts appropriated under paragraph (1) for 
15
a fiscal year, the Secretary shall reserve not more 
16
than 20 percent for carrying out subsection (f). 
17
‘‘(i) SUNSET.—The authority to award grants under 
18
subsection (a) shall be effective beginning on the date of 
19
enactment of the Emergency Access to Insulin Act of 2019 
20
and ending on the date that is 5 years after such date. 
21
‘‘(j) DEFINITIONS.—For purposes of this section: 
22
‘‘(1) ELIGIBLE INDIVIDUAL.—The term ‘eligible 
23
individual’, with respect to a program supported by 
24
a State, Indian tribe, or tribal organization receiving 
25
01:10 Aug 14, 2019
H4010
21 
•HR 4010 IH
a grant under this section, means an uninsured indi-
1
vidual or an underinsured individual— 
2
‘‘(A)(i) in the case of a grant to a State, 
3
who is a resident of the State; 
4
‘‘(ii) in the case of a grant to an Indian 
5
tribe, who is a member of such tribe; or 
6
‘‘(iii) in the case of a grant to a tribal or-
7
ganization, who is a member of the Indian tribe 
8
or Indian community served by the tribal orga-
9
nization; and 
10
‘‘(B) who has a valid prescription for insu-
11
lin that is prescribed to such individual. 
12
‘‘(2) GROUP
HEALTH
INSURANCE
COVERAGE; 
13
GROUP
HEALTH
PLAN; 
HEALTH
INSURANCE 
14
ISSUER.—The terms ‘group health insurance cov-
15
erage’, ‘group health plan’, and ‘health insurance 
16
issuer’ have the meanings given such terms in sec-
17
tion 2791. 
18
‘‘(3) HIGH-DEDUCTIBLE HEALTH PLAN.—The 
19
term ‘high-deductible health plan’ means a group 
20
health plan or group or individual health insurance 
21
coverage (offered by a health insurance issuer) that 
22
meets criteria established by the Secretary. 
23
‘‘(4) INDIAN TRIBE.—The term ‘Indian tribe’ 
24
has the meaning given such term in section 4 of the 
25
01:10 Aug 14, 2019
H4010
22 
•HR 4010 IH
Indian Health Care Improvement Act (25 U.S.C. 
1
1603). 
2
‘‘(5) INDIVIDUAL
HEALTH
INSURANCE
COV-
3
ERAGE.—The term ‘individual health insurance cov-
4
erage’ has the meaning given such term in section 
5
2791. 
6
‘‘(6) TRIBAL ORGANIZATION.—The term ‘tribal 
7
organization’ has the meaning given such term in 
8
section 4 of the Indian Health Care Improvement 
9
Act (25 U.S.C. 1603). 
10
‘‘(7) UNDERINSURED INDIVIDUAL.—The term 
11
‘underinsured individual’ means an individual who is 
12
enrolled in a high-deductible health plan. 
13
‘‘(8) UNINSURED INDIVIDUAL.—The term ‘un-
14
insured individual’ means an individual who does not 
15
have minimum essential coverage as defined in sec-
16
tion 5000A(f)(1) of the Internal Revenue Code of 
17
1986 or coverage under a medical care program of 
18
the Indian Health Service or of a tribal organization 
19
or urban Indian organization. 
20
‘‘(9) URBAN INDIAN ORGANIZATION.—The term 
21
‘urban Indian organization’ has the meaning given 
22
such term in section 4 of the Indian Health Care 
23
Improvement Act.’’. 
24
01:10 Aug 14, 2019
H4010
23 
•HR 4010 IH
(b) EXEMPTING PRICES USED UNDER AN INSULIN 
1
ASSISTANCE PROGRAM FROM BEST PRICE AND AVERAGE 
2
MANUFACTURER PRICE UNDER THE MEDICAID DRUG 
3
REBATE PROGRAM.—Section 1927 of the Social Security 
4
Act (42 U.S.C. 1396r–8) is amended— 
5
(1) in subsection (c)(1)(C)(i)(III), by inserting 
6
‘‘or under an insulin assistance program supported 
7
under section 320B of the Public Health Service 
8
Act’’ after ‘‘State pharmaceutical assistance pro-
9
gram’’; and 
10
(2) in subsection (k)(1)(B)(i)— 
11
(A) in subclause (IV), by striking ‘‘; and’’ 
12
and inserting a semicolon; 
13
(B) in subclause (V), by striking the period 
14
at the end and inserting ‘‘; and’’; and 
15
(C) by adding at the end the following new 
16
subclause: 
17
‘‘(VI) any prices used under an 
18
insulin assistance program supported 
19
under section 320B of the Public 
20
Health Service Act.’’. 
21
(c) DEDUCTIBLES FOR UNDERINSURED INDIVIDUALS 
22
PARTICIPATING IN INSULIN ASSISTANCE PROGRAMS.— 
23
Subpart I of part A of title XXVII of the Public Health 
24
01:10 Aug 14, 2019
H4010
24 
•HR 4010 IH
Service Act (42 U.S.C. 300gg et seq.) is amended by add-
1
ing at the end the following: 
2
‘‘SEC. 2710. DEDUCTIBLES FOR UNDERINSURED INDIVID-
3
UALS PARTICIPATING IN INSULIN ASSIST-
4
ANCE PROGRAMS. 
5
‘‘(a) IN GENERAL.—A group health plan that is a 
6
high-deductible health plan and a health insurance issuer 
7
offering a high-deductible health plan shall, with respect 
8
to any individual who is enrolled in such plan and obtains 
9
insulin during a plan year through an insulin card issued 
10
to the individual by a State, Indian tribe, or tribal organi-
11
zation carrying out an insulin assistance program under 
12
section 320B, count the amount the State, Indian tribe, 
13
or tribal organization pays a pharmacy for insulin for such 
14
individual for such plan year towards any deductible or 
15
other out-of-pocket expenses required to be paid under the 
16
plan. 
17
‘‘(b) HIGH-DEDUCTIBLE HEALTH PLAN.—For pur-
18
poses of this section, the term ‘high-deductible health plan’ 
19
has the meaning given such term in section 320B(j).’’. 
20
SEC. 3. ANNUAL FEES APPLICABLE TO INSULIN MANUFAC-
21
TURERS. 
22
(a) DEFINITIONS.—For purposes of this section: 
23
(1) ANNUAL PAYMENT DATE.—The term ‘‘an-
24
nual payment’’ date means, with respect to a cal-
25
02:11 Aug 14, 2019
H4010
25 
•HR 4010 IH
endar year, the date determined by the Secretary, 
1
but in no event later than September 30 of such cal-
2
endar year. 
3
(2) COVERED ENTITY.—The term ‘‘covered en-
4
tity’’, with respect to a calendar year, means an en-
5
tity that— 
6
(A) is the holder of an application ap-
7
proved under subsection (c) of section 505 of 
8
the Federal Food, Drug, and Cosmetic Act (21 
9
U.S.C. 355), or of a license issued under sub-
10
section (a) of section 351 of the Public Health 
11
Service Act (42 U.S.C. 262), for an insulin 
12
product; and 
13
(B) during the preceding calendar year, 
14
manufactured any insulin product that was sold 
15
in commerce and covered by a Federal health 
16
program at least once during such preceding 
17
calendar year. 
18
(3) INSPECTOR GENERAL.—The term ‘‘Inspec-
19
tor General’’ means the Inspector General of the De-
20
partment of Health and Human Services. 
21
(4) SECRETARY.—The term ‘‘Secretary’’ means 
22
the Secretary of Health and Human Services. 
23
(b) IMPOSITION OF FEE.—Each covered entity for a 
24
calendar year, beginning in 2020 and ending in 2024, 
25
01:10 Aug 14, 2019
H4010
26 
•HR 4010 IH
shall pay to the Secretary not later than the annual pay-
1
ment date of such calendar year a fee in an amount deter-
2
mined under subsection (c). 
3
(c) AMOUNT OF FEES.— 
4
(1) TOTAL AMOUNT.—The Secretary shall en-
5
sure that the total amount in fees assessed under 
6
subsection (b)— 
7
(A) for calendar year 2020, equals the 
8
total amount the Secretary estimates as the 
9
total expenditures for carrying out section 
10
320B of the Public Health Service Act for such 
11
calendar year; and 
12
(B) for each of calendar years 2021 
13
through 2024, equals the total amount of ex-
14
penditures the Secretary determines for car-
15
rying out such section for the preceding cal-
16
endar year. 
17
(2) DETERMINATION OF FEES FOR EACH MAN-
18
UFACTURER.— 
19
(A) FORMULA.—With respect to each cov-
20
ered entity, the fee under this section for a cal-
21
endar year shall be equal to an amount that 
22
bears the same ratio to the total amount as-
23
sessed under subsection (b) for such year as the 
24
covered entity’s sales of insulin products taken 
25
01:10 Aug 14, 2019
H4010
27 
•HR 4010 IH
into account during the preceding calendar 
1
year, bears to the aggregate sales of insulin 
2
products of all covered entities taken into ac-
3
count during such preceding calendar year. 
4
(B) SALES OF INSULIN PRODUCTS.— 
5
(i) IN
GENERAL.—For purposes of 
6
this paragraph, the sales of insulin prod-
7
ucts taken into account during any cal-
8
endar year with respect to any covered en-
9
tity shall be determined based on the total 
10
number of units of the insulin product 
11
which were sold in commerce in the pre-
12
ceding calendar year based on— 
13
(I) for a fee assessed for calendar 
14
year 2020, information obtained by 
15
the Secretary under clause (ii); and 
16
(II) for a fee assessed for each of 
17
calendar years 2021 through 2024, 
18
the information provided in the an-
19
nual reports issued by the Inspector 
20
General and made public under sec-
21
tion 4(e)(1). 
22
(ii) FEES ASSESSED FOR CALENDAR 
23
YEAR 2020.—For purposes of clause (i)(I), 
24
the Secretary shall require each covered 
25
01:10 Aug 14, 2019
H4010
28 
•HR 4010 IH
entity to submit to the Secretary informa-
1
tion on the total number of units of the in-
2
sulin product manufactured by the entity 
3
that were sold in commerce in calendar 
4
year 2019. 
5
(d) DEPOSIT.—The Secretary shall deposit amounts 
6
received through fees assessed under subsection (b) into 
7
the general fund of the Treasury. 
8
(e) ENFORCEMENT.—The Secretary may bring an ac-
9
tion in any court of competent jurisdiction to recover the 
10
amount of any fee that is assessed under subsection (b) 
11
for a calendar year and not paid by the annual payment 
12
date. 
13
SEC. 4. IDENTIFICATION OF INSULIN PRICE SPIKES; APPLI-
14
CATION OF EXCISE TAX. 
15
(a) DEFINITIONS.—In this section: 
16
(1) APPLICABLE ENTITY.—The term ‘‘applica-
17
ble entity’’ means the holder of an application ap-
18
proved under subsection (c) or (j) of section 505 of 
19
the Federal Food, Drug, and Cosmetic Act (21 
20
U.S.C. 355), or of a license issued under subsection 
21
(a) or (k) of section 351 of the Public Health Serv-
22
ice Act (42 U.S.C. 262), for an insulin product. 
23
01:10 Aug 14, 2019
H4010
29 
•HR 4010 IH
(2) COMMERCE.—The term ‘‘commerce’’ has 
1
the meaning given such term in section 4 of the 
2
Federal Trade Commission Act (15 U.S.C. 44). 
3
(3) INSPECTOR GENERAL.—The term ‘‘Inspec-
4
tor General’’ means the Inspector General of the De-
5
partment of Health and Human Services. 
6
(4) PRICE SPIKE.— 
7
(A) IN GENERAL.—The term ‘‘price spike’’ 
8
means an increase in the wholesale acquisition 
9
cost in commerce of an insulin product for 
10
which the price spike percentage is equal to or 
11
greater than the applicable price increase allow-
12
ance. 
13
(B) 
PRICE
SPIKE
PERCENTAGE.—The 
14
price spike percentage is the percentage (if any) 
15
by which— 
16
(i) the wholesale acquisition cost of an 
17
insulin product in commerce for the cal-
18
endar year; exceeds 
19
(ii) the wholesale acquisition cost of 
20
such insulin product in commerce for the 
21
calendar year preceding such year. 
22
(C) APPLICABLE PRICE INCREASE ALLOW-
23
ANCE.—The applicable price increase allowance 
24
for any calendar year is the percentage (round-
25
01:10 Aug 14, 2019
H4010
30 
•HR 4010 IH
ed to the nearest one-tenth of 1 percent) by 
1
which the C–CPI–U (as defined in section 
2
1(f)(6) of the Internal Revenue Code of 1986) 
3
for that year exceeds the C–CPI–U for the pre-
4
ceding calendar year. 
5
(5) PRICE SPIKE REVENUE.— 
6
(A) IN GENERAL.—The price spike revenue 
7
for any calendar year is an amount equal to— 
8
(i) the gross price spike revenue; 
9
minus 
10
(ii) the adjustment amount. 
11
(B) GROSS PRICE SPIKE REVENUE.—The 
12
gross price spike revenue for any calendar year 
13
is an amount equal to the product of— 
14
(i) an amount equal to the difference 
15
between clause (i) of paragraph (4)(B) and 
16
clause (ii) of such paragraph; and 
17
(ii) the total number of units of the 
18
insulin product which were sold in com-
19
merce in such calendar year. 
20
(C) ADJUSTMENT AMOUNT.—The adjust-
21
ment amount is the amount, if any, of the gross 
22
price spike revenue which the Inspector General 
23
has determined is due solely to an increase in 
24
01:10 Aug 14, 2019
H4010
31 
•HR 4010 IH
the cost of the inputs necessary to manufacture 
1
the insulin product subject to the price spike. 
2
(b) SUBMISSION BY PHARMACEUTICAL COMPANIES 
3
OF INFORMATION TO INSPECTOR GENERAL.— 
4
(1) IN
GENERAL.—For each insulin product, 
5
the applicable entity shall submit to the Inspector 
6
General a quarterly report that includes the fol-
7
lowing: 
8
(A) For each insulin product of the appli-
9
cable entity— 
10
(i) the total number of units of the in-
11
sulin product which were sold in commerce 
12
in the preceding calendar quarter; 
13
(ii) the average and median wholesale 
14
acquisition cost per unit of such insulin 
15
product in commerce in the preceding cal-
16
endar quarter, disaggregated by month; 
17
and 
18
(iii) the gross revenues from sales of 
19
such insulin product in commerce in the 
20
preceding calendar quarter. 
21
(B) Such information related to increased 
22
input costs or public health considerations as 
23
the applicable entity may wish the Inspector 
24
General to consider in making a determination 
25
01:10 Aug 14, 2019
H4010
32 
•HR 4010 IH
under clause (ii) of subsection (c)(2)(B) or an 
1
assessment in clause (iii) of such subsection for 
2
the preceding calendar quarter. 
3
(C) Such information related to any antici-
4
pated increased input costs for the subsequent 
5
calendar quarter as the applicable entity may 
6
wish the Inspector General to consider in mak-
7
ing a determination under clause (ii) of sub-
8
section (c)(2)(B) or an assessment in clause 
9
(iii) of such subsection for such calendar quar-
10
ter. 
11
(2) PENALTY FOR FAILURE TO SUBMIT.— 
12
(A) IN GENERAL.—An applicable entity de-
13
scribed in paragraph (1) that fails to submit in-
14
formation to the Inspector General regarding 
15
an insulin product, as required by such para-
16
graph, before the date specified in paragraph 
17
(3) shall be liable for a civil penalty, as deter-
18
mined under subparagraph (B). 
19
(B) AMOUNT OF PENALTY.—The amount 
20
of the civil penalty shall be equal to the product 
21
of— 
22
(i) an amount, as determined appro-
23
priate by the Inspector General; which is— 
24
01:10 Aug 14, 2019
H4010
33 
•HR 4010 IH
(I) not less than 0.5 percent of 
1
the gross revenues from sales of the 
2
insulin product described in subpara-
3
graph (A) for the preceding calendar 
4
year; and 
5
(II) not greater than 1 percent of 
6
the gross revenues from sales of such 
7
insulin product for the preceding cal-
8
endar year; and 
9
(ii) the number of days in the period 
10
between— 
11
(I) the applicable date specified 
12
in paragraph (3); and 
13
(II) the date on which the In-
14
spector General receives the informa-
15
tion described in paragraph (1) from 
16
the applicable entity. 
17
(3) SUBMISSION DEADLINE.—An applicable en-
18
tity shall submit each quarterly report described in 
19
paragraph (1) not later than January 17, April 18, 
20
June 15, and September 15 of each calendar year. 
21
(c) ASSESSMENT BY INSPECTOR GENERAL.— 
22
(1) IN GENERAL.—Not later than the last day 
23
in February of each year, the Inspector General, in 
24
01:10 Aug 14, 2019
H4010
34 
•HR 4010 IH
consultation with other relevant Federal agencies 
1
(including the Federal Trade Commission), shall— 
2
(A) complete an assessment of the infor-
3
mation the Inspector General received pursuant 
4
to subsection (b)(1) with respect to sales of in-
5
sulin products in the preceding calendar year; 
6
and 
7
(B) in the case of any insulin product 
8
which satisfies the conditions described in para-
9
graph (1) or (2) of subsection (d), submit a rec-
10
ommendation to the Secretary of Health and 
11
Human Services that such insulin product be 
12
exempted from application of the tax imposed 
13
under section 4192 of the Internal Revenue 
14
Code of 1986 (as added by subsection (g)) for 
15
such year. 
16
(2) ELEMENTS.—The assessment required by 
17
paragraph (1)(A) shall include the following: 
18
(A) Identification of each price spike relat-
19
ing to an insulin product in the preceding cal-
20
endar year. 
21
(B) For each price spike identified under 
22
subparagraph (A)— 
23
(i) a determination of the price spike 
24
revenue; 
25
01:10 Aug 14, 2019
H4010
35 
•HR 4010 IH
(ii) a determination regarding the ac-
1
curacy of the information submitted by the 
2
applicable entity regarding increased input 
3
costs; and 
4
(iii) an assessment of the rationale of 
5
the applicable entity for the price spike. 
6
(d) EXEMPTION OF CERTAIN INSULIN PRODUCTS.— 
7
(1) IN GENERAL.—The Secretary of Health and 
8
Human Services, upon recommendation of the In-
9
spector General pursuant to subsection (c)(1)(B), 
10
may exempt any insulin product which has been sub-
11
ject to a price spike during the preceding calendar 
12
year from application of the tax imposed under sec-
13
tion 4192 of the Internal Revenue Code of 1986 for 
14
such year, if the Secretary determines that, based on 
15
information 
submitted 
pursuant 
to 
subsection 
16
(b)(1)(B), a for-cause price increase exemption 
17
should apply. 
18
(2) CLARIFICATION.—In considering, under 
19
paragraph (1)(A), information submitted pursuant 
20
to subsection (b)(1)(B), the Secretary— 
21
(A) has the discretion to determine that 
22
such information does not warrant a for-cause 
23
price increase exemption; and 
24
01:10 Aug 14, 2019
H4010
36 
•HR 4010 IH
(B) shall exclude from such consideration 
1
any information submitted by the applicable en-
2
tity threatening to curtail or limit production of 
3
the insulin product if the Secretary does not 
4
grant an exemption from the application of the 
5
tax under section 4192 of the Internal Revenue 
6
Code of 1986. 
7
(e) REPORTS BY INSPECTOR GENERAL.— 
8
(1) PUBLIC REPORT.— 
9
(A) IN GENERAL.—Not later than the last 
10
day in February of each year, subject to sub-
11
paragraph (C), the Inspector General shall 
12
issue a report containing the information de-
13
scribed in subparagraph (B) to be made avail-
14
able to the public, including on the Internet 
15
website of the Inspector General. 
16
(B) CONTENTS.—The report issued under 
17
subparagraph (A) shall include the following: 
18
(i) The information received under 
19
subsection (b)(1) with respect to the pre-
20
ceding calendar year. 
21
(ii) The price spikes identified under 
22
subparagraph (A) of subsection (c)(2). 
23
01:10 Aug 14, 2019
H4010
37 
•HR 4010 IH
(iii) The price spike revenue deter-
1
minations made under subparagraph (B)(i) 
2
of such subsection. 
3
(iv) The determinations and assess-
4
ments made under clauses (ii) and (iii) of 
5
subparagraph (B) of such subsection. 
6
(C) PROPRIETARY INFORMATION.—The In-
7
spector General shall ensure that any informa-
8
tion made public in accordance with subpara-
9
graph (A) excludes trade secrets and confiden-
10
tial commercial information. 
11
(2) REPORT
TO
INTERNAL
REVENUE
SERV-
12
ICE.— 
13
(A) IN
GENERAL.—Subject to subpara-
14
graph (C), not later than the last day in Feb-
15
ruary of each year, the Inspector General shall 
16
transmit to the Internal Revenue Service a re-
17
port on the findings of the Inspector General 
18
with respect to the information the Inspector 
19
General received under subsection (b)(1) with 
20
respect to the preceding calendar year and the 
21
assessment carried out by the Inspector General 
22
under subsection (c)(1)(A) with respect to such 
23
information. 
24
01:10 Aug 14, 2019
H4010
38 
•HR 4010 IH
(B) CONTENTS.—The report transmitted 
1
under subparagraph (A) shall include the infor-
2
mation described in paragraph (1)(B). 
3
(C) NOTICE AND OPPORTUNITY FOR HEAR-
4
ING.— 
5
(i) IN GENERAL.—No report shall be 
6
transmitted to the Internal Revenue Serv-
7
ice under subparagraph (A) with respect to 
8
an insulin product unless the Inspector 
9
General has provided the applicable entity 
10
with— 
11
(I) the assessment of such insulin 
12
product under subsection (c)(1)(A); 
13
and 
14
(II) notice of their right to a 
15
hearing in regards to such assess-
16
ment. 
17
(ii) NOTICE.—The notice required 
18
under clause (i) shall be provided to the 
19
applicable entity not later than 30 days 
20
after completion of the assessment under 
21
subsection (c)(1)(A). 
22
(iii) REQUEST
FOR
HEARING.—Sub-
23
ject to clause (v), an applicable entity may 
24
request a hearing before the Secretary of 
25
01:10 Aug 14, 2019
H4010
39 
•HR 4010 IH
Health and Human Services not later than 
1
30 days after the date on which the notice 
2
under clause (ii) is received. 
3
(iv) COMPLETION
OF
HEARING.—In 
4
the case of an applicable entity which re-
5
quests a hearing pursuant to clause (iii), 
6
the Secretary of Health and Human Serv-
7
ices shall, not later than 12 months after 
8
the date on which the assessment under 
9
subsection (c)(1)(A) was completed by the 
10
Inspector General— 
11
(I) make a final determination in 
12
regards the accuracy of such assess-
13
ment; and 
14
(II) provide the report described 
15
in subparagraph (B) to the Internal 
16
Revenue Service. 
17
(v) LIMITATION.—An applicable entity 
18
may request a hearing under clause (iii) 
19
with respect to a particular insulin product 
20
only once within a 5-year period. 
21
(f) NOTIFICATION.—The Secretary of the Treasury 
22
shall notify, at such time and in such manner as the Sec-
23
retary of the Treasury shall provide, each applicable entity 
24
in regard to any insulin product which has been deter-
25
01:10 Aug 14, 2019
H4010
40 
•HR 4010 IH
mined to have been subject to a price spike during the 
1
preceding calendar year and the amount of the tax im-
2
posed on such applicable entity pursuant to section 4192 
3
of the Internal Revenue Code of 1986. 
4
(g) EXCISE TAX ON INSULIN PRODUCTS SUBJECT TO 
5
PRICE SPIKES.— 
6
(1) IN GENERAL.—Subchapter E of chapter 32 
7
of the Internal Revenue Code of 1986 is amended by 
8
adding at the end the following new section: 
9
‘‘SEC. 4192. INSULIN PRODUCTS SUBJECT TO PRICE SPIKES. 
10
‘‘(a) IMPOSITION OF TAX.— 
11
‘‘(1) IN GENERAL.—Subject to paragraph (3), 
12
for each taxable insulin product sold by an applica-
13
ble entity during the calendar year, there is hereby 
14
imposed on such entity a tax equal to the greater 
15
of— 
16
‘‘(A) the annual price spike tax for such 
17
insulin product, or 
18
‘‘(B) subject to paragraph (2), the cumu-
19
lative price spike tax for such insulin product. 
20
‘‘(2) LIMITATION.—In the case of a taxable in-
21
sulin product for which the applicable period (as de-
22
termined under subsection (c)(2)(E)(i)) is less than 
23
2 calendar years, the cumulative price spike tax shall 
24
not apply. 
25
01:10 Aug 14, 2019
H4010
41 
•HR 4010 IH
‘‘(3) EXEMPTION.—For any calendar year in 
1
which the Secretary of Health and Human Services 
2
has provided an exemption for a taxable insulin 
3
product pursuant to section 4(d) of the Emergency 
4
Access to Insulin Act of 2019, the amount of the tax 
5
determined under paragraph (1) for such insulin 
6
product for such calendar year shall be reduced to 
7
zero. 
8
‘‘(b) ANNUAL PRICE SPIKE TAX.— 
9
‘‘(1) IN GENERAL.—The amount of the annual 
10
price spike tax shall be equal to the applicable per-
11
centage of the price spike revenue received by the 
12
applicable entity on the sale of the taxable insulin 
13
product during the calendar year. 
14
‘‘(2) APPLICABLE PERCENTAGE.—For purposes 
15
of paragraph (1), the applicable percentage shall be 
16
equal to— 
17
‘‘(A) in the case of a taxable insulin prod-
18
uct which has been subject to a price spike per-
19
centage greater than the applicable price in-
20
crease 
allowance 
(as 
defined 
in 
section 
21
4(a)(4)(C) of the Emergency Access to Insulin 
22
Act of 2019) but less than 15 percent, 50 per-
23
cent, 
24
01:10 Aug 14, 2019
H4010
42 
•HR 4010 IH
‘‘(B) in the case of a taxable insulin prod-
1
uct which has been subject to a price spike per-
2
centage equal to or greater than 15 percent but 
3
less than 20 percent, 75 percent, and 
4
‘‘(C) in the case of a taxable insulin prod-
5
uct which has been subject to a price spike per-
6
centage equal to or greater than 20 percent, 
7
100 percent. 
8
‘‘(c) CUMULATIVE PRICE SPIKE TAX.— 
9
‘‘(1) IN GENERAL.—The amount of the cumu-
10
lative price spike tax shall be equal to the applicable 
11
percentage of the cumulative price spike revenue re-
12
ceived by the applicable entity on the sale of the tax-
13
able insulin product during the calendar year. 
14
‘‘(2) APPLICABLE PERCENTAGE.— 
15
‘‘(A) IN GENERAL.—For purposes of para-
16
graph (1), the applicable percentage shall be 
17
equal to— 
18
‘‘(i) in the case of a taxable insulin 
19
product which has been subject to a cumu-
20
lative price spike percentage greater than 
21
the cumulative price increase allowance but 
22
less than the first multi-year percentage, 
23
50 percent, 
24
01:10 Aug 14, 2019
H4010
43 
•HR 4010 IH
‘‘(ii) in the case of a taxable insulin 
1
product which has been subject to a cumu-
2
lative price spike percentage equal to or 
3
greater than the first multi-year percent-
4
age but less than the second multi-year 
5
percentage, 75 percent, and 
6
‘‘(iii) in the case of a taxable insulin 
7
product which has been subject to a cumu-
8
lative price spike percentage equal to or 
9
greater than the second multi-year percent-
10
age, 100 percent. 
11
‘‘(B) CUMULATIVE PRICE SPIKE PERCENT-
12
AGE.—The cumulative price spike percentage is 
13
the percentage (if any) by which— 
14
‘‘(i) the wholesale acquisition cost of 
15
the taxable insulin product in commerce 
16
for the preceding calendar year, exceeds 
17
‘‘(ii) the wholesale acquisition cost of 
18
such insulin product in commerce for the 
19
base year. 
20
‘‘(C) CUMULATIVE
PRICE
INCREASE
AL-
21
LOWANCE.—For purposes of clause (i) of sub-
22
paragraph (A), the cumulative price increase al-
23
lowance for any calendar year is the percentage 
24
(rounded to the nearest one-tenth of 1 percent) 
25
01:10 Aug 14, 2019
H4010
44 
•HR 4010 IH
by which the C–CPI–U (as defined in section 
1
1(f)(6)) for that year exceeds the C–CPI–U for 
2
the base year. 
3
‘‘(D) MULTI-YEAR
PERCENTAGES.—For 
4
purposes of subparagraph (A), the first multi- 
5
year percentage and second multi-year percent-
6
age shall be determined in accordance with the 
7
following table: 
8
‘‘Number of years in applicable period 
First 
multi-year 
percentage 
Second 
multi-year 
percentage 
2 years ....................................................................
17.5 
22.5
3 years ....................................................................
20.0 
25.0
4 years ....................................................................
22.5 
27.5
5 years ....................................................................
25.0 
30.0. 
‘‘(E) APPLICABLE
PERIOD
AND
BASE 
9
YEAR.— 
10
‘‘(i) APPLICABLE PERIOD.—The appli-
11
cable period shall be the lesser of— 
12
‘‘(I) the 5 preceding calendar 
13
years, 
14
‘‘(II) all calendar years beginning 
15
after the date of enactment of this 
16
section, or 
17
‘‘(III) all calendar years in which 
18
the taxable insulin product was sold in 
19
commerce. 
20
01:10 Aug 14, 2019
H4010
45 
•HR 4010 IH
‘‘(ii) BASE
YEAR.—The base year 
1
shall be the calendar year immediately pre-
2
ceding the applicable period. 
3
‘‘(3) CUMULATIVE
PRICE
SPIKE
REVENUE.— 
4
For purposes of paragraph (1), the cumulative price 
5
spike revenue for any taxable insulin product shall 
6
be an amount equal to— 
7
‘‘(A) an amount equal to the product of— 
8
‘‘(i) an amount (not less than zero) 
9
equal to— 
10
‘‘(I) the wholesale acquisition 
11
cost of such insulin product in com-
12
merce for the preceding calendar year, 
13
minus 
14
‘‘(II) the wholesale acquisition 
15
cost of such insulin product in com-
16
merce for the base year, and 
17
‘‘(ii) the total number of units of such 
18
insulin product which were sold in com-
19
merce in the preceding calendar year, 
20
minus 
21
‘‘(B) an amount equal to the sum of the 
22
adjustment amounts, if any, determined under 
23
section 4(a)(5)(C) of the Emergency Access to 
24
01:10 Aug 14, 2019
H4010
46 
•HR 4010 IH
Insulin Act of 2019 for each calendar year dur-
1
ing the applicable period. 
2
‘‘(d) DEFINITIONS.—For purposes of this section— 
3
‘‘(1) TAXABLE INSULIN PRODUCT.—The term 
4
‘taxable insulin product’ means an insulin product 
5
which has been identified by the Inspector General 
6
of the Department of Health and Human Services, 
7
under section 4(c)(2)(A) of the Emergency Access to 
8
Insulin Act of 2019, as being subject to a price 
9
spike. 
10
‘‘(2) OTHER TERMS.—The terms ‘applicable en-
11
tity’, ‘price spike’, ‘price spike percentage’, and 
12
‘price spike revenue’ have the same meaning given 
13
such terms under section 4(a) of the Emergency Ac-
14
cess to Insulin Act of 2019.’’. 
15
(2) CLERICAL AMENDMENTS.— 
16
(A) The heading of subchapter E of chap-
17
ter 32 of the Internal Revenue Code of 1986 is 
18
amended by striking ‘‘Medical Devices’’ 
19
and inserting ‘‘Certain Medical Devices 
20
and Insulin Products’’. 
21
(B) The table of subchapters for chapter 
22
32 of such Code is amended by striking the 
23
item relating to subchapter E and inserting the 
24
following new item: 
25
‘‘SUBCHAPTER E. CERTAIN MEDICAL DEVICES AND INSULIN PRODUCTS’’. 
01:10 Aug 14, 2019
H4010
47 
•HR 4010 IH
(C) The table of sections for subchapter E 
1
of chapter 32 of such Code is amended by add-
2
ing at the end the following new item: 
3
‘‘Sec. 4192. Insulin products subject to price spikes.’’. 
(3) EFFECTIVE DATE.—The amendments made 
4
by this subsection shall apply to sales after the date 
5
of the enactment of this Act. 
6
SEC. 5. BIOLOGICAL PRODUCT EXCLUSIVITY. 
7
(a) IN GENERAL.—Section 351(k)(7)(A) of the Pub-
8
lic Health Service Act (42 U.S.C. 262(k)(7)(A)) is amend-
9
ed by striking ‘‘12 years’’ and inserting ‘‘7 years’’. 
10
(b) 
CONFORMING
AMENDMENTS.—Paragraphs 
11
(2)(A) and (3)(A) of section 351(m) of the Public Health 
12
Service Act (42 U.S.C. 262(m)) is amended by striking 
13
‘‘12 years’’ each place it appears and inserting ‘‘7 years’’. 
14
Æ 
01:10 Aug 14, 2019
H4010
